Avicanna reports Q2 revenue $6.16M, up 1% vs. 2Q24

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Aug 14 2025

0mins

Company Performance: Avicanna achieved positive adjusted EBITDA for the first half of 2025, reflecting strong financial discipline and operational focus, alongside growth in multiple commercial channels in Canada.
Strategic Positioning: The company's advancements in its pipeline and engagement with the Canadian medical community position it well for both domestic and international expansion.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.